NASDAQ:ABUS - Arbutus Biopharma Corporation
$3.18
 $-0.19
-5.64%
4:00PM EDT
2019-04-18
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ABUS     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 84   199. 07   233. 87  
42 stocks rank:  3. 48 K 1. 43 K 1. 06 K
# analyst opinions:  7. 00   14. 48   14. 09  
mean recommendation:  1. 90   2. 09   2. 01  

quick ratio:  11. 25   5. 29   1. 92  
current ratio:  11. 50   5. 64   2. 40  

target price low:  4. 14   84. 50   115. 74  
target price avg:  5. 50   110. 73   137. 39  
target price high:  9. 32   136. 41   157. 80  
1-yr high:  12. 35   114. 11   138. 85  
last close:  3. 18   87. 56   116. 78  
50-day avg:  3. 88   95. 43   123. 53  
200-day avg:  6. 08   94. 13   121. 20  
1-yr low:  3. 18   72. 67   98. 41  
volume:  214. 39 K 2. 43 M 4. 85 M
50-day avg volume:  193. 69 K 2. 72 M 4. 97 M
200-day avg volume:  342. 77 K 2. 90 M 4. 58 M

1-day return:  -5. 64 % -0. 40 % 0. 07 %
this week return:  -14. 75 % -5. 72 % -4. 11 %
12-wk return:  -19. 70 % 1. 78 % -0. 04 %
52-wk return:  -27. 43 % 10. 81 % 14. 09 %

enterprise value (EV):  220. 95 M 51. 19 B 117. 96 B
market cap:  178. 46 M 43. 00 B 104. 52 B
EBITDA:  -67. 99 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -3. 25   4. 34   13. 27  
enterprise/revenue (EV/R):  37. 17   68. 16   13. 68  
total revenue:  5. 95 M 10. 61 B 38. 24 B
total debt:  0. 00   12. 22 B 16. 66 B
net income (common):  -67. 15 M 2. 20 B 4. 21 B

shares outstanding:  56. 12 M 570. 91 M 1. 24 B
shares:  28. 58 M 571. 02 M 1. 23 B
shares short:  908. 71 K 9. 93 M 16. 79 M
shares short prior month:  929. 19 K 9. 96 M 16. 58 M
short ratio:  4. 88   5. 31   3. 30  
short % of float:  2. 60 % 5. 81 % 2. 61 %
total cash/share:  2. 22   11. 13   9. 30  
total cash:  124. 62 M 6. 70 B 7. 10 B
free cash flow:  -41. 70 M 3. 58 B 4. 74 B
operating cash flow:  -67. 87 M 4. 14 B 6. 32 B

book value:  1. 33   12. 76   26. 84  
price/book:  2. 38   3. 08   -1. 74  
gross profits:  -51. 99 M 8. 03 B 34. 77 B
operating margins:  -1180. 35 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  0. 00 % 37. 02 % 55. 68 %

1-yr max volatility:  -33. 99 % --- ---
1-yr mean volatility:  -0. 04 % 0. 03 % 0. 04 %

1-yr EPS:  -1. 21   2. 39   4. 08  
forward EPS:  -1. 42   3. 97   7. 14  
P/E:  -2. 62   13. 59   22. 83  
forward P/E:  -2. 63   -20. 05   14. 49  
PE/G:  0. 08   -1. 46   1. 68  
growth:  -33. 80 % 126. 81 % 29. 29 %
earnings high:  -0. 37   1. 02   1. 63  
earnings avg:  -0. 39   0. 76   1. 51  
earnings low:  -0. 43   0. 47   1. 39  
revenue high:  700. 00 K 2. 68 B 10. 71 B
revenue avg:  220. 00 K 2. 59 B 10. 49 B
revenue low:  -0. 00   2. 49 B 10. 25 B
return on assets:  -18. 86 % -2. 80 % 5. 29 %
return on equity:  -29. 82 % -18. 52 % 7. 38 %
revenue growth:  -33. 80 % 92. 55 % 19. 15 %
revenue/share:  0. 11   13. 27   55. 24  

beta (1yr vs S&P500):  2. 18   1. 24   0. 93  
sharpe (1yr):  -0. 13   0. 29   0. 60  

held % insiders:  40. 87 % 6. 38 % 3. 38 %
held % institutions:  44. 06 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : ABUS
.    + 0.569 =         0.569 :: INITIAL WEIGHT
.   + 38.368 =        38.937 :: spline projection addition
.    x 1.432 =        55.759 :: industry recommendation factor
.    x 2.331 =         130.0 :: symbol recommendation factor
.    x 1.545 =       200.882 :: EV/R factor
.    x 0.998 =       200.503 :: return on assets factor
.    x 0.997 =       199.905 :: return on equity factor
.    x 0.997 =       199.229 :: revenue growth factor
.    x 2.039 =       406.269 :: current ratio factor
.    x 1.048 =       425.626 :: quick ratio factor
.    x 1.098 =       467.204 :: short ratio factor
.    x 2.024 =       945.537 :: price-to-book factor
.    x 2.132 =      2015.755 :: P/E weight
.    x 1.895 =      3820.453 :: PE/G factor
.    x 1.339 =      5113.815 :: beta factor
.    x 0.125 =       639.337 :: sharpe factor
.    x 1.575 =      1007.165 :: target low factor
.    x 1.285 =      1293.919 :: target mean factor
.    x 1.139 =      1473.715 :: target high factor
.    x 1.312 =      1932.995 :: industry 2-weeks return factor
.    x 0.933 =      1803.212 :: "drift" penalty 3 days ago
.    x 0.907 =      1634.655 :: "drift" penalty 4 days ago
.    x 0.911 =      1489.866 :: "drift" penalty 5 days ago
.    x 0.749 =      1116.515 :: overall "drift" factor
.    x 0.998 =      1114.828 :: largest single-day jump factor
.    x 0.071 =        79.631 :: low price factor
.      x 1.0 =        79.618 :: factor hist industry gain for week 15
.   cubeRoot =         4.302 :: reduced to standardize
.    - 25.92 =          0.84 :: add/subtract for performance
.                       0.84 :: FINAL WEIGHT for NASDAQ:ABUS


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org